Stem cell genes are helping inform this startup’s approach to cancer diagnostics
The same genes in stem cells and cancer cells are being expressed. OncoCyte is using this knowledge to develop a genetic diagnostic test.
The same genes in stem cells and cancer cells are being expressed. OncoCyte is using this knowledge to develop a genetic diagnostic test.
Cleveland stem cell technology developer Cell Targeting has sold its assets to BioTime, which specializes in stem cells for use in regenerative medicine and blood plasma volume expanders for use in surgery. The deal includes $250,000 in cash and about 262,000 shares of BioTime's common stock. Joseph Wagner, Cell Targeting's president, will become the chief executive at OncoCyte, a BioTime subsidiary.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
In the last week at MedCity News: Cell Targeting in Cleveland points stem cell therapies to specific areas of the body, Cleveland insurance broker and risk manager Oswald Cos. assembles panel that says health care reforms are too close to call, and Ohio State University and Battelle try to energize joint research and economic development efforts.
Cell Targeting is developing technology that can point stem cell therapies to specific areas of the body. Among the many challenges in cell therapy is direction: not enough of the stem cells are getting to the tissues that needs treatment. But the company also wants to sell companies (and investors) on the idea that Cell Targeting's approach can create new products.
The money will push two stem-cell technologies deeper into clinical trials and create Ohio's first Pluripotent Stem Cell Facility.
CLEVELAND, Ohio — Stem-cell companies may be able to blunt the economic doldrums of 2009 with new opportunities courtesy of a new administration, according to the interim chief executive of Cleveland’s Cell Targeting Inc. Cell Targeting on Thursday said it appointed Joseph Wagner as its chief technology officer. Wagner for the last seven years worked […]